Webinar | July 20, 2017

Optimize Biologic Drug Development With The Power Of Scientific Informatics

Source: Dassault Systemes Americas

Many organizations in the pharmaceutical and biopharmaceutical industries have increased their efforts in biotherapeutic drug development to remain competitive by shifting their activities away from small molecule toward biologics drug development.

The complex structure of Biologics, the nature of the interactions with their partners, require accurate modelling method to predict their physicochemical properties and ultimately accelerate innovation and bring better products to market faster.

Register for this webinar to learn how your organization can benefit from the BIOVIA Biologics design solution:

  • Sequence annotation and alignment
  • Identification of post-translational modification sites
  • Automatic antibody modelling cascade including full-length and bispecific antibodies
  • Epitope / Paratope detection
  • Affinity maturation
  • Prediction of antibody stability
  • Prediction of aggregation propensity
  • Biophysical property prediction for developability

Presented by:

Dr. Hugues-Olivier Bertrand

Senior Director, Life Science Research

Pre-Sales, Sr. Fellow, BIOVIA Science Council

Dassault Systèmes BIOVIA


Dr. Anne Goupil-Lamy

Principal Field Application Scientist

Fellow, BIOVIA Science Council

Dassault Systèmes BIOVIA